高血脂症动物模型研究进展
|
摘要
随着人们生活方式的改变,生活质量的不断提高,高血脂症成为现代常见临床疾病。目前对于高血脂症的治疗以药物治疗为主。与西药相比,中药治疗高血脂症的机制复杂,但鲜有不良反应发生。为探究其病理病机,寻找预防和治疗措施,阐明中药治疗高血脂症的优势和特色,需要建立与人类高血脂症相类似的动物模型。动物模型是实验研究的基础,动物模型的建立方法要尽量与病程发展相吻合,动物模型的评价指标也要尽量与临床指标相对应。理想的高血脂症模型应该具备造模方法可重复、操作简单、成本较低、便于推广等特点。目前高血脂症动物模型的研究方法众多,化学诱导是最常用的方法,实验动物主要是大鼠、小鼠,先天性模型和转基因模型较为少用。不同动物的生物特性不同,适合的造模方法也不尽相同。根据实验目的、实验周期、实验技术等因素,选择合适的模型动物和造模方法是高血脂症实验成功的关键。本文对近年来国内外过高血脂症模型动物的选择、造模方法及对应的模型评价指标进行归纳总结,为降脂中药新药开发者研究、选择和建立高血脂症动物模型提供参考。
With the change of people's life style and the improvement of living quality,hyperlipidemia has become a common clinical disease. At present,the treatment of hyperlipidemia is mainly based on drug therapy. As compared with western medicine,the mechanism of traditional Chinese medicine( TCM) for treating hyperlipidemia is complicated, but the adverse reactions are fewer. In order to explore its pathological pathogenesis,find prevention and treatment measures,and elucidate the advantages and features of TCM in treating hyperlipidemia,we need to establish an animal model that is similar to human hyperlipidemia. The animal model is the basis for experimental research,so the establishment of the animal model should be consistent with the development of the disease process,and the assessment indicators of the animal model should also correspond to the clinical indicators as far as possible. The ideal hyperlipidemia model should have the characteristics of repeatability,simple operation,low cost,and easy promotion. At present,there are many research methods for animal models of hyperlipidemia,and chemical induction is the most commonly used method. The experimental animals mainly include rats and mice,while the congenital models and transgenic models are rarely used. The biological characteristics of different animals are different,so their modeling methods are also different. According to the experimental objectives,period,techniques and other factors,selecting the right model animal and modeling method are the key to the success of hyperlipidemia experiments. This paper would summarize the recent experimental studies of hyperlipidemia animal models both at home and abroad in terms of animal selection,modeling methods and evaluation indicators of model,which will provide reference and basis for the hypolipidemic developers to study,choose and establish hyperlipidemia animal models.
With the change of people's life style and the improvement of living quality,hyperlipidemia has become a common clinical disease. At present,the treatment of hyperlipidemia is mainly based on drug therapy. As compared with western medicine,the mechanism of traditional Chinese medicine( TCM) for treating hyperlipidemia is complicated, but the adverse reactions are fewer. In order to explore its pathological pathogenesis,find prevention and treatment measures,and elucidate the advantages and features of TCM in treating hyperlipidemia,we need to establish an animal model that is similar to human hyperlipidemia. The animal model is the basis for experimental research,so the establishment of the animal model should be consistent with the development of the disease process,and the assessment indicators of the animal model should also correspond to the clinical indicators as far as possible. The ideal hyperlipidemia model should have the characteristics of repeatability,simple operation,low cost,and easy promotion. At present,there are many research methods for animal models of hyperlipidemia,and chemical induction is the most commonly used method. The experimental animals mainly include rats and mice,while the congenital models and transgenic models are rarely used. The biological characteristics of different animals are different,so their modeling methods are also different. According to the experimental objectives,period,techniques and other factors,selecting the right model animal and modeling method are the key to the success of hyperlipidemia experiments. This paper would summarize the recent experimental studies of hyperlipidemia animal models both at home and abroad in terms of animal selection,modeling methods and evaluation indicators of model,which will provide reference and basis for the hypolipidemic developers to study,choose and establish hyperlipidemia animal models.
引文
[1]王跃,王恒哲,杨露.高血脂症药物开发的发展态势分析[J].生物产业技术,2016,5:89-98.
[2]刘晶,崔建华.高脂血症的中药治疗进展[J].天津药学,2017,29(3):70-74.
[3]PATTANAMONGKOL PEERANAN(林雨欣).治疗高脂血症方剂的配伍应用探讨[D].南京:南京中医药大学,2017.
[4]孙晓倩,孙蓉.大鼠脂肪肝肝郁脾虚证的模型[J].中国实验方剂学杂志,2017,23(10):92-98.
[5]刘楠,姜云耀,李莹,等.气滞血瘀证动物模型研究现状[J].中国实验方剂学杂志,2018,24(1):217-226.
[6]王颖,于学慧.高脂血症动物模型研究进展[J].中国老年学杂志,2015,35(19):5654-5657.
[7]陈慧敏.豚鼠动脉粥样硬化模型的建立及机理探讨[D].北京:中国协和医科大学,2010.
[8]Bozoky Z,Balogh L,Mathe D,et al.Evaluation of rat and rabbit sera lipoproteins in experimentally induced hyperlipidemia by analytical ultracentrifugation[J].Eur Biophys J,2006,35(3):205-213.
[9]杨丽,张小娜.动脉粥样硬化动物模型研究概况[J].广东药学,2005,21(2):1-3.
[10]柳玉霞,王学林,李树良,等.大鼠与家兔高脂血症模型造模方法及特点的比较[J].中国实用医药,2007,2(8):12-13.
[11]李泽坤,邓嘉鑫,申彪,等.高血脂家兔动脉铸型技术方法的初探[C]∥中国解剖学会科技开发和咨询工作委员会.中国解剖学会第六届全国解剖学技术学术会议论文汇编:2017年卷.中国解剖学会科技开发和咨询工作委员会,2017:2.
[12]刘五州.当归挥发油对高脂血症模型动物血脂及动脉粥样硬化形成的影响[D].兰州:甘肃中医药大学,2016.
[13]管仲莹,朱竞赫,秦文艳,等.不同配方高脂乳剂家兔高脂血症模型的研究[J].中华中医药学刊,2016,34(8):1974-1977.
[14]雷晓林,彭菊,李俊葵,等.迈康片对高脂血症大鼠血管保护的作用机制研究[J].中国实验方剂学杂志,2015,21(2):151-155.
[15]赵文萃,张宁,周慧琴,等.三七总黄酮对高血脂大鼠血脂的影响[J].中国实验方剂学杂志,2016,22(8):143-147.
[16]吴栩,韦伟标,刘少斌.高脂血症大鼠模型4种造模方法的筛选及优化[J].动物医学进展,2013,34(9):75-78.
[17]尹震花,张伟,冯发进,等.黑莓籽降血脂有效部位研究[J].中国实验方剂学杂志,2014,20(24):194-198.
[18]梁红峰,陈方.高脂血症模型小鼠生化指标的变化[J].广东微量元素科学,2004,11(4):42-45.
[19]玄瑛美,张广平,马丽娜,等.双黄调脂方及其有效成分发挥降脂作用的探讨[J].中国实验方剂学杂志,2017,23(10):79-84.
[20]潘雪刁,王惠好,何冰,等.苦瓜水提取物对高脂血症小鼠的降血脂作用研究[J].中国实验方剂学杂志,2013,19(14):265-267.
[21]李亚梅,吴萍,谢雪姣,等.铁皮石斛对Apo E(-/-)小鼠血脂及TNF-α,IL-6的影响[J].中国实验方剂学杂志,2013,19(18):270-274.
[22]郭曙光,康文艺,许启泰.植物油和动物油建立小鼠高脂血症模型研究[J].中成药,2009,31(11):1748-1750.
[23]Fernandez M L,Wood R J.Guinea pigs as models for cholesterol and lipoprotein metabolism[J].J Nutr,2001,131(1):10-20.
[24]安韵霏.蚯蚓有效成分对豚鼠脂代谢影响的研究[D].长沙:湖南农业大学,2015.
[25]徐登峰.中药复方清脂胶囊对高脂饲养豚鼠主动脉炎症因子的作用[D].石家庄:河北医科大学,2015.
[26]谢亚菲,蒋学华,王凌,等.Dunkin Hartley白化豚鼠和Hartley花色豚鼠高脂造模以及降脂药效学的比较[J].中国比较医学杂志,2015,25(9):56-61.
[27]杨关林,张会永,庞琳琳,等.跑步运动联合高脂单笼喂饲建立巴马小型猪高脂血症脾虚痰浊证动物模型[J].中华中医药学刊,2016,34(9):2055-2060.
[28]郭金英,李华,谢人明.金黄地鼠高血脂模型的建立[J].中国实验动物学报,2007,15(1):5-7.
[29]蒙田秀,龚志强,黄振园,等.白鹤灵芝不同提取部位抗鹌鹑高血脂症及动脉粥样硬化的影响[J].中国实验方剂学杂志,2014,20(8):166-169.
[30]王林元,王淳,张建军,等.美藤果油对高脂血症鹌鹑血脂及载脂蛋白影响[J].中国公共卫生,2015,31(7):893-896.
[31]韩冰.斑马鱼高血脂模型的建立及小檗胺降血脂机制研究[D].重庆:西南大学,2016.
[32]陈侃,王长谦,范虞琪,等.斑马鱼血管内脂代谢研究方法的构建[J].中国动脉硬化杂志,2017,25(4):398-403.
[33]倪鸿昌,李俊,金涌,等.大鼠实验性高脂血症和高脂血症性脂肪肝模型研究[J].中国药理学通报,2004,20(6):703-706.
[34]吕建敏,应华忠,徐孝平,等.高脂血症动物模型研究进展[J].浙江中医学院学报,2005,29(4):87-89.
[35]苗明三.实验动物和动物实验技术[M].北京:中国中医药出版社,1997:200.
[36]Watanabe Y.Serial inbreeding of rabbits with hereditary hyperlipidemia and atherosclerosis(WHHL rabbit):incidence and development of atherosclerosis and xanthoma[J].Atherosclerosis,1980,36(2):261-268.
[37]Aliev G,Burnstock G.Watanabe rabbits with heritable hypercholesterolaemia:a model of atherosclerosis[J].Histol Histopathol,1998,13(3):797-817.
[38]Beaty T H,Prenger V L,Virgil D G,et al.A genetic model for control of hypertriglyceridemia and apolipoprotein B levels in the Johns Hopkins colony of St.Thomas Hospital rabbits[J].Genetics,1992,132(132):1095-1104.
[39]丁正磊.菊苣组分N1、N2对高甘油三酯并高尿酸血症模型动物的影响及机理研究[D].北京:北京中医药大学,2005.
[40]胡慧明,朱彦陈,朱巧巧,等.实验性高脂血症动物模型比较分析[J].中国中药杂志,2016,41(20):3709-3714.
[41]徐小妹,林文津,张亚敏,等.泽泻汤降脂作用与肠道微生态的相关性探讨[J].中国实验方剂学杂志,2017,23(3):116-121.
[42]熊静悦,周桢昊,赵璐,等.脂肪乳剂建立高脂血症模型小鼠的比较研究[J].中华中医药学刊,2006,24(8):1507-1508.
[43]周星,刘黎明,孙海涛,等.脂肪乳剂建立大鼠高脂血症模型的研究[J].中国普外基础与临床杂志,2012,19(10):1085-1088.
[44]严家荣,王弋,刘盛来,等.2种高脂血症大鼠模型比较[J].中国药业,2017,26(8):5-7.
[45]Zarzecki M S,Araujo S M,Bortolotto V C,et al.Hypolipidemic action of chrysin on Triton WR-1339-induced hyperlipidemia in female C57BL/6 mice[J].Toxicology Reports,2014,1:200-208.
[46]包雪梅,那生桑,陆景坤.荜茇有效部位群的调血脂研究[J].中国中药杂志,2013,38(6):909-913.
[47]Johnston T P,LI Y,Jamal A S,et al.Poloxamer 407-induced atherosclerosis in mice appears to be due to lipid derangements and not due to its direct effects on endothelial cells and macrophages[J].Mediators of Inflammation,2003,12(3):147-155.
[48]Acker C I,Nogueira C W.Chlorpyrifos acute exposure induces hyperglycemia and hyperlipidemia in rats[J].Chemosphere,2012,89(5):602-608.
[49]Szkudelski T.The mechanism of alloxan and streptozotocin action inβcells of the rat pancreas[J].Physiol Res,2001,50(6):537-546.
[50]冯任南,郭福川,李颖,等.急性高血脂小鼠模型蛋黄乳及Trition法建立[J].中国公共卫生,2010,26(9):1116-1117.
[51]李红涛,张婷婷,马波,等.瑞舒伐他汀对poloxamer407诱导的小鼠高血脂模型血脂水平的影响[J].世界临床药物,2012,33(3):156-159.
[52]王大为,许秀颖,刘婷婷.玉米花丝饮品对高脂血症鼠的降血脂作用[J].吉林大学学报:医学版,2007,33(6):1029-1032.
[53]刘婷,陈然,陈頔,等.用CGMCC No.8730冠突散囊菌发酵的金花黑茶对两种血脂异常模型大鼠体质量和血脂的作用[J].卫生研究,2016,45(4):637-642.
[54]Chaturvedi U,Shrivastava A,Bhadauria S,et al.A mechanism-based pharmacological evaluation of efficacy of Trigonella foenum graecum(fenugreek)seeds in regulation of dyslipidemia and oxidative stress in hyperlipidemic rats[J].J Cardiovasc Pharmacol,2013,61(6):505-512.
[55]王培琴,杨东升,孙静,等.钨酸钠对泊洛沙姆407诱导高血脂昆明小鼠模型血脂的影响[J].武警后勤学院学报:医学版,2013,22(4):249-251.
[56]樊林花,刘茂林,刘田福.人类疾病基因工程动物模型的研究与应用[J].医学综述,2009,15(7):1009-1012.
[57]倪鸿昌,李俊.高血脂症实验性动物模型的研究进展[J].安徽医药,2004,8(6):401-403.
[58]魏泓.医学实验动物学[M].2版.成都:四川科技出版社,2001:637.
[59]Jones G W,Mcleod L,Kennedy C L,et al.Imbalanced gp130 signalling in Apo E-deficient mice protects against atherosclerosis.[J].Atherosclerosis,2015,238(2):321-328.
[60]Vik R,Brattelid T,Skorve J,et al.A water-soluble extract of chicken reduced plasma triacylglycerols,but showed no anti-atherosclerotic activity in apo E-/-mice[J].J Nutr,2015,2(1/2):8-14.
[61]Patterson K A,ZHANG X,Wrobleski S K,et al.Rosuvastatin reduced deep vein thrombosis in Apo E gene deleted mice with hyperlipidemia through non-lipid lowering effects[J].Thromb Res,2013,131(3):268-276.
[62]陆宗良.血脂、脂蛋白及载脂蛋白的基本概念(续前)[J].中国循环杂志,2009,24(4):315-316.
[63]韦唯.沙棘—枸杞保健品对血脂调节功能及其毒性研究[D].呼和浩特:内蒙古农业大学,2013.
[64]王抒,李健斋.血清总胆固醇与低密度脂蛋白胆固醇水平的相对关系[J].中国动脉硬化杂志,2003,11(2):161-162.
[2]刘晶,崔建华.高脂血症的中药治疗进展[J].天津药学,2017,29(3):70-74.
[3]PATTANAMONGKOL PEERANAN(林雨欣).治疗高脂血症方剂的配伍应用探讨[D].南京:南京中医药大学,2017.
[4]孙晓倩,孙蓉.大鼠脂肪肝肝郁脾虚证的模型[J].中国实验方剂学杂志,2017,23(10):92-98.
[5]刘楠,姜云耀,李莹,等.气滞血瘀证动物模型研究现状[J].中国实验方剂学杂志,2018,24(1):217-226.
[6]王颖,于学慧.高脂血症动物模型研究进展[J].中国老年学杂志,2015,35(19):5654-5657.
[7]陈慧敏.豚鼠动脉粥样硬化模型的建立及机理探讨[D].北京:中国协和医科大学,2010.
[8]Bozoky Z,Balogh L,Mathe D,et al.Evaluation of rat and rabbit sera lipoproteins in experimentally induced hyperlipidemia by analytical ultracentrifugation[J].Eur Biophys J,2006,35(3):205-213.
[9]杨丽,张小娜.动脉粥样硬化动物模型研究概况[J].广东药学,2005,21(2):1-3.
[10]柳玉霞,王学林,李树良,等.大鼠与家兔高脂血症模型造模方法及特点的比较[J].中国实用医药,2007,2(8):12-13.
[11]李泽坤,邓嘉鑫,申彪,等.高血脂家兔动脉铸型技术方法的初探[C]∥中国解剖学会科技开发和咨询工作委员会.中国解剖学会第六届全国解剖学技术学术会议论文汇编:2017年卷.中国解剖学会科技开发和咨询工作委员会,2017:2.
[12]刘五州.当归挥发油对高脂血症模型动物血脂及动脉粥样硬化形成的影响[D].兰州:甘肃中医药大学,2016.
[13]管仲莹,朱竞赫,秦文艳,等.不同配方高脂乳剂家兔高脂血症模型的研究[J].中华中医药学刊,2016,34(8):1974-1977.
[14]雷晓林,彭菊,李俊葵,等.迈康片对高脂血症大鼠血管保护的作用机制研究[J].中国实验方剂学杂志,2015,21(2):151-155.
[15]赵文萃,张宁,周慧琴,等.三七总黄酮对高血脂大鼠血脂的影响[J].中国实验方剂学杂志,2016,22(8):143-147.
[16]吴栩,韦伟标,刘少斌.高脂血症大鼠模型4种造模方法的筛选及优化[J].动物医学进展,2013,34(9):75-78.
[17]尹震花,张伟,冯发进,等.黑莓籽降血脂有效部位研究[J].中国实验方剂学杂志,2014,20(24):194-198.
[18]梁红峰,陈方.高脂血症模型小鼠生化指标的变化[J].广东微量元素科学,2004,11(4):42-45.
[19]玄瑛美,张广平,马丽娜,等.双黄调脂方及其有效成分发挥降脂作用的探讨[J].中国实验方剂学杂志,2017,23(10):79-84.
[20]潘雪刁,王惠好,何冰,等.苦瓜水提取物对高脂血症小鼠的降血脂作用研究[J].中国实验方剂学杂志,2013,19(14):265-267.
[21]李亚梅,吴萍,谢雪姣,等.铁皮石斛对Apo E(-/-)小鼠血脂及TNF-α,IL-6的影响[J].中国实验方剂学杂志,2013,19(18):270-274.
[22]郭曙光,康文艺,许启泰.植物油和动物油建立小鼠高脂血症模型研究[J].中成药,2009,31(11):1748-1750.
[23]Fernandez M L,Wood R J.Guinea pigs as models for cholesterol and lipoprotein metabolism[J].J Nutr,2001,131(1):10-20.
[24]安韵霏.蚯蚓有效成分对豚鼠脂代谢影响的研究[D].长沙:湖南农业大学,2015.
[25]徐登峰.中药复方清脂胶囊对高脂饲养豚鼠主动脉炎症因子的作用[D].石家庄:河北医科大学,2015.
[26]谢亚菲,蒋学华,王凌,等.Dunkin Hartley白化豚鼠和Hartley花色豚鼠高脂造模以及降脂药效学的比较[J].中国比较医学杂志,2015,25(9):56-61.
[27]杨关林,张会永,庞琳琳,等.跑步运动联合高脂单笼喂饲建立巴马小型猪高脂血症脾虚痰浊证动物模型[J].中华中医药学刊,2016,34(9):2055-2060.
[28]郭金英,李华,谢人明.金黄地鼠高血脂模型的建立[J].中国实验动物学报,2007,15(1):5-7.
[29]蒙田秀,龚志强,黄振园,等.白鹤灵芝不同提取部位抗鹌鹑高血脂症及动脉粥样硬化的影响[J].中国实验方剂学杂志,2014,20(8):166-169.
[30]王林元,王淳,张建军,等.美藤果油对高脂血症鹌鹑血脂及载脂蛋白影响[J].中国公共卫生,2015,31(7):893-896.
[31]韩冰.斑马鱼高血脂模型的建立及小檗胺降血脂机制研究[D].重庆:西南大学,2016.
[32]陈侃,王长谦,范虞琪,等.斑马鱼血管内脂代谢研究方法的构建[J].中国动脉硬化杂志,2017,25(4):398-403.
[33]倪鸿昌,李俊,金涌,等.大鼠实验性高脂血症和高脂血症性脂肪肝模型研究[J].中国药理学通报,2004,20(6):703-706.
[34]吕建敏,应华忠,徐孝平,等.高脂血症动物模型研究进展[J].浙江中医学院学报,2005,29(4):87-89.
[35]苗明三.实验动物和动物实验技术[M].北京:中国中医药出版社,1997:200.
[36]Watanabe Y.Serial inbreeding of rabbits with hereditary hyperlipidemia and atherosclerosis(WHHL rabbit):incidence and development of atherosclerosis and xanthoma[J].Atherosclerosis,1980,36(2):261-268.
[37]Aliev G,Burnstock G.Watanabe rabbits with heritable hypercholesterolaemia:a model of atherosclerosis[J].Histol Histopathol,1998,13(3):797-817.
[38]Beaty T H,Prenger V L,Virgil D G,et al.A genetic model for control of hypertriglyceridemia and apolipoprotein B levels in the Johns Hopkins colony of St.Thomas Hospital rabbits[J].Genetics,1992,132(132):1095-1104.
[39]丁正磊.菊苣组分N1、N2对高甘油三酯并高尿酸血症模型动物的影响及机理研究[D].北京:北京中医药大学,2005.
[40]胡慧明,朱彦陈,朱巧巧,等.实验性高脂血症动物模型比较分析[J].中国中药杂志,2016,41(20):3709-3714.
[41]徐小妹,林文津,张亚敏,等.泽泻汤降脂作用与肠道微生态的相关性探讨[J].中国实验方剂学杂志,2017,23(3):116-121.
[42]熊静悦,周桢昊,赵璐,等.脂肪乳剂建立高脂血症模型小鼠的比较研究[J].中华中医药学刊,2006,24(8):1507-1508.
[43]周星,刘黎明,孙海涛,等.脂肪乳剂建立大鼠高脂血症模型的研究[J].中国普外基础与临床杂志,2012,19(10):1085-1088.
[44]严家荣,王弋,刘盛来,等.2种高脂血症大鼠模型比较[J].中国药业,2017,26(8):5-7.
[45]Zarzecki M S,Araujo S M,Bortolotto V C,et al.Hypolipidemic action of chrysin on Triton WR-1339-induced hyperlipidemia in female C57BL/6 mice[J].Toxicology Reports,2014,1:200-208.
[46]包雪梅,那生桑,陆景坤.荜茇有效部位群的调血脂研究[J].中国中药杂志,2013,38(6):909-913.
[47]Johnston T P,LI Y,Jamal A S,et al.Poloxamer 407-induced atherosclerosis in mice appears to be due to lipid derangements and not due to its direct effects on endothelial cells and macrophages[J].Mediators of Inflammation,2003,12(3):147-155.
[48]Acker C I,Nogueira C W.Chlorpyrifos acute exposure induces hyperglycemia and hyperlipidemia in rats[J].Chemosphere,2012,89(5):602-608.
[49]Szkudelski T.The mechanism of alloxan and streptozotocin action inβcells of the rat pancreas[J].Physiol Res,2001,50(6):537-546.
[50]冯任南,郭福川,李颖,等.急性高血脂小鼠模型蛋黄乳及Trition法建立[J].中国公共卫生,2010,26(9):1116-1117.
[51]李红涛,张婷婷,马波,等.瑞舒伐他汀对poloxamer407诱导的小鼠高血脂模型血脂水平的影响[J].世界临床药物,2012,33(3):156-159.
[52]王大为,许秀颖,刘婷婷.玉米花丝饮品对高脂血症鼠的降血脂作用[J].吉林大学学报:医学版,2007,33(6):1029-1032.
[53]刘婷,陈然,陈頔,等.用CGMCC No.8730冠突散囊菌发酵的金花黑茶对两种血脂异常模型大鼠体质量和血脂的作用[J].卫生研究,2016,45(4):637-642.
[54]Chaturvedi U,Shrivastava A,Bhadauria S,et al.A mechanism-based pharmacological evaluation of efficacy of Trigonella foenum graecum(fenugreek)seeds in regulation of dyslipidemia and oxidative stress in hyperlipidemic rats[J].J Cardiovasc Pharmacol,2013,61(6):505-512.
[55]王培琴,杨东升,孙静,等.钨酸钠对泊洛沙姆407诱导高血脂昆明小鼠模型血脂的影响[J].武警后勤学院学报:医学版,2013,22(4):249-251.
[56]樊林花,刘茂林,刘田福.人类疾病基因工程动物模型的研究与应用[J].医学综述,2009,15(7):1009-1012.
[57]倪鸿昌,李俊.高血脂症实验性动物模型的研究进展[J].安徽医药,2004,8(6):401-403.
[58]魏泓.医学实验动物学[M].2版.成都:四川科技出版社,2001:637.
[59]Jones G W,Mcleod L,Kennedy C L,et al.Imbalanced gp130 signalling in Apo E-deficient mice protects against atherosclerosis.[J].Atherosclerosis,2015,238(2):321-328.
[60]Vik R,Brattelid T,Skorve J,et al.A water-soluble extract of chicken reduced plasma triacylglycerols,but showed no anti-atherosclerotic activity in apo E-/-mice[J].J Nutr,2015,2(1/2):8-14.
[61]Patterson K A,ZHANG X,Wrobleski S K,et al.Rosuvastatin reduced deep vein thrombosis in Apo E gene deleted mice with hyperlipidemia through non-lipid lowering effects[J].Thromb Res,2013,131(3):268-276.
[62]陆宗良.血脂、脂蛋白及载脂蛋白的基本概念(续前)[J].中国循环杂志,2009,24(4):315-316.
[63]韦唯.沙棘—枸杞保健品对血脂调节功能及其毒性研究[D].呼和浩特:内蒙古农业大学,2013.
[64]王抒,李健斋.血清总胆固醇与低密度脂蛋白胆固醇水平的相对关系[J].中国动脉硬化杂志,2003,11(2):161-162.